Jiangsu Hengrui Medicine (SHA:600276) will conduct clinical trials on SHR-2173 injection after receiving approval from the Chinese drug administration, according to a Shanghai Stock Exchange filing on Friday.
The drug will be tested as a treatment for lupus nephritis, the pharmaceutical company said.
Hengrui Medicine's shares slipped more than 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments